Prospective study on the survival of HCC patients treated with transcatheter arterial lipiodol chemoembolization

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 1039-1042

  Mao, Ying Min ^a   Luo, Zu Yan ^a   Li, Bo ^a   Hu, Ting Yang ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

China; HCC; Survival; TACE

Indexed keywords

ETHIODIZED OIL;

ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871703009     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.1039     Document Type: Article

References (22)

1. Bruix J, Castells A, Montanya X, et al (1994). Phase II study of transarterial embolisation in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology, 20, 643-50.
2. Chen MF, Hwang TL, Jeng LB, et al (1994). Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg, 129, 738-42.
3. Chin PL, Chu DZJ, Clarke KG, et al (1999). Ethnic differences in the behavior of hepatocellular carcinoma. Cancer, 85, 1931-6.
4. Choi BI, Kim HC, Han JK, et al (1992). Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathological findings. Radiology, 182, 709-13.
5. Doyon DMA, Jourde AM, Regensberg C, et al (1974). L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol, 17, 593-603.
6. Farinati F, De Maria N, Marafin C, et al (1996). Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci, 41, 2332-9.
7. Huppert PE, Geissier F, Duda SH, et al (1994). Chemoembolisation deshepatozellularen karzinom: computertomographische befunde unf klinische resultate bei prospektiv repetitiver therapie. Rofo Forschr Geb Rontgenstr Neuen Bildgeb Verfahr, 160, 425-32.
8. Ikeda K, Kumada H, Saitoh S, et al (1991). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model. Cancer, 68, 2150-4.
9. Imamura H, Matsuyama Y, Tanaka E, et al (2003). Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol, 38, 200-7.
10. Koda M, Murawaki Y, Mitsuda A, et al (2000). Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer, 88, 529-37.
11. Konno T, Maeda H, Iwai K, et al (1983). Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol, 19, 1053-65.
12. Lee HS, Kim KM, Yoon JH, et al (2002). Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol, 20, 4459-65.
13. Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17.
14. Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet, 359, 1734-9.
15. Lo CM, Ngan H, Tso WK, et al (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 35, 1164-71.
16. Lopez RR, Pan SH, Hoffman L, et al (2002). Comparison of transarterial chemoembolization in patients with unresectable diffuse vs. focal hepatocellular carcinoma. Arch Surg, 137, 653-8.
17. Mondazzi L, Bottelli R, Brambilla G, et al (1994). Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology, 19, 1115-23.
18. Nakamura H, Tanaka T, Hori S, et al (1983). Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology, 147, 401-5.
19. Okuda K, Obata H, Ohtsuki T, et al (1984). Prognosis of primary hepatocellular carcinoma. Hepatology, 4, S3-6.
20. Raoul JL, Hersebach D, Bretagne JF, et al (1992). Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmokinetics of doxorubicin. Cancer, 70, 585-90.
21. Savastano S, Miotto D, Casarrubea G, et al (1999). Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol, 28, 334-40.
22. Solomon B, Soulen MC, Baum RA, et al (1999). Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. J Vasc Interv Radiol, 10, 793-8.